Vaccine titer testing: avoiding false security in immune-deficient kids

Even outside replacement therapy, antibody levels can decline quickly, while commercially available serology does not measure the full cellular immune response.

That makes vaccine titer testing for immunocompromised children useful—but only when the result is interpreted alongside treatment history, immune phenotype, vaccine type, timing, and the clinical question being asked. A number on a laboratory report is not a substitute for an immunization plan.

In my experience working with clinical cohorts, the most consequential error is not always an incorrect assay. It is asking the assay to answer a question it was never designed to answer: whether a child is broadly protected against infection.

The IVIG conundrum: when serology reflects the donor pool

Immunoglobulin replacement therapy complicates almost every discussion of post-vaccination antibody levels in pediatric patients. IVIG and SCIG contain pooled antibodies collected from donors. Those antibodies can include activity against common vaccine antigens, including antigens from routine childhood immunizations.

If a blood sample is taken while a child is receiving immunoglobulin replacement, a positive antibody result may reflect passively transferred donor immunoglobulin. It may not demonstrate that the child’s B cells responded to vaccination, produced durable antibody, or formed meaningful endogenous immune memory.

This is not a minor interpretive footnote. It changes the clinical meaning of the result.

A child with severe antibody deficiency can produce a reassuring-looking serology report while remaining dependent on replacement immunoglobulin for protection. The laboratory result may be analytically correct and clinically misleading at the same time. That is why vaccine titer testing during active IVIG or SCIG therapy cannot be treated as a clean measurement of the child’s own humoral response.

Timing is part of the test

When clinicians need to reassess endogenous humoral immunity after IVIG has been discontinued, the relevant question is not simply whether the last infusion occurred recently. Passive antibodies need time to decline. The available clinical guidance cited in this area commonly uses a four- to six-month interval after stopping IVIG before reassessing the child’s own antibody response.

That interval is not a universal guarantee of interpretive clarity. Pharmacokinetics, the product used, dosing schedule, underlying immune defect, and the specific antigen being measured all matter. Still, testing too soon can create a false impression of immune competence.

The same caution applies to SCIG, although the administration pattern differs. Repeated subcutaneous dosing can maintain passive antibody exposure over time, so the treatment timeline must be reviewed rather than inferred from the date of one appointment.

Before interpreting a titer, the clinical team needs to know:

• Whether the child is currently receiving IVIG or SCIG.
• The date and pattern of recent doses.
• Which vaccine antigens are being measured.
• Whether the child has a defined B-cell, T-cell, combined, or broader immune deficiency.
• Whether the result is being used to diagnose an antibody defect, assess vaccine response, or decide on revaccination.
• Whether the child has had breakthrough infections despite replacement therapy or documented vaccination.

A positive titer during immunoglobulin replacement may describe the product being infused, not the child’s immune memory.

What should happen after a misleading result?

A low titer during IVIG is not automatically proof that vaccination failed. A high titer during IVIG is not proof that the child responded. In both cases, the treatment context limits the conclusion.

The appropriate response is usually to reconstruct the question:

1. Is the goal to diagnose an endogenous antibody deficiency?

2. Is the goal to document response to a specific vaccine?

3. Is the goal to decide whether a child can safely receive another dose?

4. Is the goal to estimate current protection against a particular pathogen?

5. Is the goal to assess whether an immune defect has improved after treatment?

Each question may require a different panel, a different interval, or a different kind of evidence. Repeating the same serology without changing the clinical context is not a strategy. It is often just more data with the same limitation.

Polysaccharide and conjugate vaccines answer different questions

A second source of confusion is the assumption that all pneumococcal antibody results measure the same immune function. They do not.

Protein-conjugated vaccines and plain polysaccharide vaccines stimulate the immune system through different mechanisms. That distinction matters when clinicians are evaluating whether a child can respond to polysaccharide antigens.

Routine childhood pneumococcal immunization generally includes protein-conjugated pneumococcal vaccines, commonly referred to as PCV. Assessment of a broader polysaccharide response may involve the 23-valent pneumococcal polysaccharide vaccine, or PPSV23. Looking at both types of response can provide more information than relying on one vaccine category alone.

A child may have evidence of response to protein-conjugated antigens but show a limited response to nonconjugated polysaccharide antigens. That pattern can be clinically relevant in the evaluation of specific antibody deficiency and related humoral immune problems. Conversely, a result from one vaccine type should not be casually generalized to every vaccine-preventable pathogen.

The exact interpretation depends on the child’s age, vaccine history, immune phenotype, assay method, and timing. It also depends on whether the antibody measurement represents a true response rather than passively transferred immunoglobulin.

Why Salmonella typhi testing may enter the discussion

In children being evaluated for antibody deficiency while receiving or recently having received immunoglobulin replacement, clinicians may need an antigen that is less likely to be represented in standard IVIG products. Antibodies against Salmonella typhi polysaccharide antigens can be useful in this setting because they are generally absent from standard intravenous immunoglobulin preparations.

That does not make the assay a universal solution. It remains one component of a broader evaluation, and the clinical team still has to account for the child’s vaccination history, timing, assay characteristics, and immune phenotype. But it illustrates a central principle of serological interpretation: the selected antigen matters.

A panel is only as informative as the biological question behind it. Measuring several common vaccine titers during passive antibody exposure can produce a larger report without producing a clearer answer.

Antibodies are not the entire immune response

Commercial vaccine titer testing measures antibodies. It does not directly measure T-cell mediated immunity against vaccine-preventable pathogens.

That limitation becomes particularly important in children with combined immune defects, T-cell abnormalities, immune dysregulation, or complex treatment histories. A child can have low antibody levels without the result fully describing cellular immune function. Another child can have detectable antibodies while still carrying clinically significant immune impairment.

The precise degree to which cellular immunity compensates for low antibody titers varies by pathogen and immune defect. There is no universal serum threshold that guarantees complete protection from breakthrough infection across all pediatric immunosuppressive treatments or immune deficiencies.

This is where the language of efficacy endpoints becomes important. A laboratory endpoint—such as a detectable antibody concentration—is not identical to a clinical endpoint, such as prevention of infection, hospitalization, complications, or transmission. Surrogate markers can be useful, but they must not be promoted into guarantees they cannot support.

For children undergoing oncology treatment, for example, the interpretation of vaccination response may be affected by chemotherapy, the timing of treatment, hematologic recovery, and the underlying disease. A low post-vaccination antibody level may reflect impaired response, waning immunity, treatment-related suppression, or passive-antibody interference. It cannot be interpreted in isolation.

In clinical research, I would not accept a serological endpoint without asking what outcome it predicts and in which cohort. The same standard should apply in pediatric care.

What a titer cannot tell you

A vaccine titer cannot independently establish:

• That a child will not develop the infection.
• That protection is durable.
• That the child has adequate T-cell mediated immunity.
• That the child responded to vaccination if IVIG or SCIG is affecting the sample.
• That one antigen response represents immunity to every antigen in the vaccine schedule.
• That a live vaccine is safe to administer.
• That revaccination is appropriate without reviewing the underlying immune defect.

This is not an argument against serology. It is an argument against using serology as a stand-in for clinical judgment.

Live vaccines require immune thresholds, not optimism

Live attenuated vaccines demand a separate level of caution because the risk calculation changes when the immune system cannot control replication of the vaccine strain.

Live vaccines—including oral polio vaccine, BCG, and live attenuated influenza vaccine—are strictly contraindicated in children with severe B-cell immunodeficiencies such as X-linked agammaglobulinemia and severe T-cell immunodeficiencies such as SCID.

The same rule cannot simply be extended to every child labeled as having an immunodeficiency. Nor can the presence of a mild or partial diagnosis be treated as automatic clearance. Live vaccine decisions should be tied to the child’s actual immune profile, not to a reassuring general description.

Children with 22q11.2 deletion syndrome demonstrate why the details matter. Live MMR and varicella vaccines may be administered at 12 months only when specific immune criteria are met, including a CD4 count of at least 400 cells/mm³ and a CD8 count of at least 200 cells/mm³. Those thresholds are not decorative laboratory values. They are part of the safety assessment.

A vaccine titer does not replace lymphocyte subset analysis when the question is whether a live vaccine can be given. Antibody levels cannot establish that a child has sufficient T-cell competence for that decision.

A practical distinction clinicians should keep visible

There are three separate questions that are often collapsed into one:

1. Did the child receive the vaccine?

2. Did the child produce a measurable antibody response?

3. Can the child safely receive a live vaccine now?

The first may be answered through reliable records. The second may involve serology, provided the timing and treatment history support interpretation. The third requires immune assessment that may include lymphocyte subsets and diagnosis-specific criteria.

A positive answer to question two does not automatically answer question three.

Vaccination history is evidence—but not always adequate evidence

In immunocompromised pediatric patients, oral recall of vaccination history is a weak foundation for high-stakes decisions. Families may remember that a child received routine immunizations without knowing the product, date, dose number, or whether a dose was administered during a period of immune suppression. Records can be incomplete, duplicated, or inconsistent across health systems.

That creates two opposing risks:

• Under-vaccination because valid doses are missing from the available record.
• Unnecessary over-immunization because clinicians assume doses were never given.

The solution is not to dismiss the family’s account. It is to treat recall as a starting point rather than definitive documentation. Registry data, primary care records, specialist notes, oncology treatment timelines, and state or regional immunization systems may each resolve part of the history.

For children receiving immune-modifying treatment, the date of vaccination must be interpreted alongside the date and intensity of therapy. A vaccine administered during profound immune suppression may not produce the expected response, but that does not mean the child should automatically receive another dose. The decision depends on vaccine type, disease state, immune recovery, safety constraints, and the treating team’s plan.

When low titers should not trigger automatic revaccination

The phrase when to re-vaccinate after low titer results sounds straightforward. In practice, it is not.

A low result may represent:

• An absent or inadequate endogenous response.
• Antibody decay after an initially adequate response.
• Testing performed during or too soon after immunoglobulin therapy.
• A vaccine-specific gap that does not reflect global immune failure.
• An assay limitation.
• A response altered by chemotherapy or another immunosuppressive treatment.
• A mismatch between the vaccine history and the antigen being measured.

Before another dose is administered, clinicians need to determine whether the result is actionable. Revaccination may be inappropriate or unsafe for some live vaccines, particularly in severe B-cell or T-cell immunodeficiency. It may also provide little information if the child remains unable to mount a response or if passive antibodies continue to confound testing.

A better sequence is:

1. Verify the vaccination record as far as possible.

2. Map the result to the specific antigen and vaccine platform.

3. Review IVIG or SCIG exposure and the interval since treatment.

4. Characterize the underlying immune deficiency and current immune counts.

5. Separate antibody-response questions from live-vaccine safety questions.

6. Decide whether repeat testing, revaccination, prophylaxis, or continued replacement therapy addresses the actual clinical risk.

This is slower than reacting to a red or green laboratory flag. It is also more defensible.

The real clinical utility of serological testing

The clinical utility of serological testing for vaccines is strongest when the test changes a decision that could not be made reliably from the history and immune evaluation alone.

A useful result may help identify impaired antibody production, document a response to selected antigens, distinguish response patterns between conjugated and polysaccharide vaccines, or support a broader diagnosis of humoral immune dysfunction. It can also identify situations in which a reported vaccination history does not match measurable antibody findings—although that mismatch still requires interpretation rather than automatic correction.

The test is less useful when it is ordered as a broad reassurance exercise. Testing every available titer in a child on IVIG may produce a long list of detectable antibodies without answering whether the child can make them independently. Repeating titers without a defined endpoint can generate statistical-looking noise rather than clinically meaningful evidence.

In trial design, we separate exploratory biomarkers from validated efficacy endpoints. Pediatric immunology should maintain the same discipline. A biomarker can inform the decision without becoming the decision.

The strongest vaccine assessment is not the largest antibody panel. It is the one that answers a defined clinical question without ignoring the immune system around it.

A sober route through the laboratory report

For families and clinicians, the practical route is to read the titer report as one layer of evidence.

Start with treatment exposure. If IVIG or SCIG is active or recent, passive antibodies may limit the meaning of positive results. If the goal is to measure endogenous immunity, the timing of reassessment matters, with four to six months after discontinuation commonly used before attempting a clearer evaluation.

Next, identify the vaccine platform. Responses to protein-conjugated vaccines and polysaccharide vaccines should not be treated as interchangeable. The pneumococcal comparison between PCV and PPSV23 can be particularly informative when evaluating polysaccharide responsiveness.

Then assess the immune phenotype. Severe B-cell and T-cell deficiencies change the safety profile of live vaccines. In 22q11.2 deletion syndrome, decisions about MMR and varicella at 12 months depend on immune thresholds such as CD4 above 400 cells/mm³ and CD8 above 200 cells/mm³. A titer alone cannot substitute for these criteria.

Finally, separate protection from detection. Detectable antibody is not the same as guaranteed clinical protection, and a low antibody result does not describe T-cell mediated immunity. The unknowns are real, especially across different immunosuppressive therapies and immune deficiency syndromes.

Final verdict: useful test, dangerous shortcut

Vaccine titer testing for immunocompromised children remains clinically valuable, but only within a disciplined framework. IVIG and SCIG can create false-positive serological results. Antibody decay can make an old response look absent. Conjugated and polysaccharide vaccines probe different aspects of humoral function. Titer assays do not measure cellular immunity. And live-vaccine safety requires immune profiling, not a reassuring antibody number.

The correct interpretation is therefore conditional, not binary. A result should be read against the child’s treatment timeline, immune phenotype, vaccine record, and the precise endpoint under consideration.

My sober view is that serology is best used as an instrument—not as a verdict. When the clinical question is clear, it can expose meaningful immune deficits and guide safer decisions. When it is used to manufacture reassurance, especially during immunoglobulin replacement, it creates precisely the false security that high-risk children cannot afford.